The material from precedent disorder and/or CH or CCUS is not always available for MDS and AML patients, and early genetic alterations, like somatic TP53 mutations, cannot be tracked back, limiting the feasibility of applying mutant p53 as a prognostic biomarker in therapy-related AML or secondary AML. This evidence concerns the gene TP53 and myelodysplastic syndrome.